IRB Review of Adverse Events in Investigational Drug Studies [Book Review]

&
IRB: Ethics & Human Research 19 (6):1 (1997)
  Copy   BIBTEX

Abstract

This article has no associated abstract. (fix it)

Categories

Keywords

Reprint years

DOI

10.2307/3564433

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 92,758

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Cost‐effectiveness of an electronic medication ordering and administration system in reducing adverse drug events.Robert C. Wu, Audrey Laporte & Wendy J. Ungar - 2007 - Journal of Evaluation in Clinical Practice 13 (3):440-448.
Selective review of external adverse events: one IRB's response to the avalanche of IND safety reports.Bruce Gordon & Ernest Prentice - 1998 - IRB: Ethics & Human Research 21 (3):10-11.
Physicians' attitudes towards voluntary reporting of adverse drug events.Adolfo Figueiras, Fernando Tato, Jesus Fontainas, Bahi Takkouche & Juan Jesus Gestal-Otero - 2001 - Journal of Evaluation in Clinical Practice 7 (4):347-354.
A targeted method for standardized assessment of adverse drug events in surgical patients.Monica Boer, Jordy Js Kiewiet, Eveline B. Boeker, Maya A. Ramrattan, Marcel Gw Dijkgraaf & Marja A. Boermeester - 2013 - Journal of Evaluation in Clinical Practice 19 (6):1073-1082.
An evaluation of risk factors for adverse drug events associated with angiotensin‐converting enzyme inhibitors.Takeshi Morimoto, Tejal K. Gandhi, Julie M. Fiskio, Andrew C. Seger, Joseph W. So, E. Francis Cook, Tsuguya Fukui & David W. Bates - 2004 - Journal of Evaluation in Clinical Practice 10 (4):499-509.
Screening for adverse events.Andrew S. Karson & David W. Bates - 1999 - Journal of Evaluation in Clinical Practice 5 (1):23-32.
Factors that influence spontaneous reporting of adverse drug reactions: a model centralized in the medical professional.Maria T. Herdeiro, Jorge Polonia, Juan J. Gestal-Otero & Adolfo Figueiras - 2004 - Journal of Evaluation in Clinical Practice 10 (4):483-489.
Understanding pharmacist decision making for adverse drug event (ADE) detection.Shobha Phansalkar, Jennifer M. Hoffman, John F. Hurdle & Vimla L. Patel - 2009 - Journal of Evaluation in Clinical Practice 15 (2):266-275.
Ethical Issues in New Drug Prescribing.Lindsay W. Cole, Jennifer C. Kesselheim & Aaron S. Kesselheim - 2012 - Journal of Bioethical Inquiry 9 (1):77-83.
Characteristics associated with the occurrence of adverse events: a retrospective medical record review using the Global Trigger Tool in a fully digitalized tertiary teaching hospital in Korea.Jee-In Hwang, Ho Jun Chin & Yoon-Seok Chang - 2014 - Journal of Evaluation in Clinical Practice 20 (1):27-35.
Do we need a concept of intraoperative complication?J. Wilson - unknown
A call to restructure the drug development process: Government over-regulation and non-innovative late stage (phase III) clinical trials are major obstacles to advances in health care.Thomas C. Jones - 2005 - Science and Engineering Ethics 11 (4):575-587.
Incidence and preventability of adverse events requiring intensive care admission: a systematic review.Annemie Vlayen, Sandra Verelst, Geertruida E. Bekkering, Ward Schrooten, Johan Hellings & Neree Claes - 2012 - Journal of Evaluation in Clinical Practice 18 (2):485-497.
Evaluation of drug toxicity in clinical trials.Jacek Spławiński, Jerzy Kuźniar, Krzysztof Filipiak & Waldemar Zieliński - 2006 - Science and Engineering Ethics 12 (1):139-145.

Analytics

Added to PP
2014-03-25

Downloads
17 (#889,074)

6 months
8 (#407,549)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

Mindsets, Informed Consent, and Research.Lynn A. Jansen - 2013 - Hastings Center Report 44 (1):25-32.

Add more citations

References found in this work

No references found.

Add more references